HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avon

This article was originally published in The Rose Sheet

Executive Summary

Reaffirmed third quarter financial guidance includes U.S. sales growth of 7% and order growth of 3%. Company says temporary interruption in U.S. mail deliveries in days immediately following Sept. 11 caused some delays in receiving orders from representatives but that order flow has returned to normal. "The past two weeks have encouraged us that the resiliency of our U.S. representatives and the personal relationships they have with their customers continue to be powerful, competitive advantages particularly in times of uncertainty," Avon states. Company is scheduled to report third quarter financials Oct. 17

Latest Headlines
See All
UsernamePublicRestriction

Register

RS009658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel